(Q74686984)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9636804 AND SRC:MED&resulttype=core&format=json

12 November 2019

review article

1 reference

title

Immunotherapy as an effective tool in allergy treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9636804 AND SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

H. J. Malling

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:9636804

27 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9636804

27 December 2024

publication date

1 May 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9636804 AND SRC:MED&resulttype=core&format=json

12 November 2019

May 1998

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9636804

full work available at URL

27 December 2024

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1398-9995.1998.tb04082.x

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:9636804

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111/j.1398-9995.1998.tb04082.x

27 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1398-9995.1998.tb04082.x

27 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

27 December 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9636804 AND SRC:MED&resulttype=core&format=json

12 November 2019

volume

53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9636804 AND SRC:MED&resulttype=core&format=json

12 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9636804 AND SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

461-472

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9636804 AND SRC:MED&resulttype=core&format=json

Position paper: Immunotherapy

12 November 2019

cites work

2

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever

27 December 2024

5

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Rinkel injection therapy: a multicenter controlled study

27 December 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Clinical and immunologic evaluation of glutaraldehyde-modified tyrosine-adsorbed short ragweed extract: a double-blind, placebo-controlled trial

27 December 2024

7

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Grass pollen hyposensitization versus placebo therapy. I. Clinical effectiveness and methodological aspects of a pre-seasonal course of desensitization with a four-grass pollen extract

27 December 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

A double-blind, placebo-controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy.

27 December 2024

9

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Aggressive coseasonal immunotherapy in mountain cedar pollen allergy

27 December 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever

27 December 2024

11

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever

27 December 2024

12

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy

27 December 2024

13

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis. A controlled clinical trial

27 December 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Asthma as a variable in a study of immunotherapy for allergic rhinitis

27 December 2024

15

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis

27 December 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Polyethylene glycol-modified ragweed pollen extract in rhinoconjunctivitis

27 December 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

A double-blind placebo-controlled trial of polymerized whole grass administered in an accelerated dosage schedule for immunotherapy of grass pollinosis

27 December 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Double-blind, placebo-controlled immunotherapy with a high-molecular-weight, formalinized allergoid in grass pollen allergy

27 December 2024

20

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract

27 December 2024

21

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

The safety and activity of polymerized ragweed: a double-blind, placebo-controlled trial in 81 patients with ragweed rhinitis

27 December 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy.

27 December 2024

23

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma

27 December 2024

25

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

A double-blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac) in patients with perennial rhinitis. 1. Clinical aspects.

27 December 2024

26

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Suppression of the late cutaneous response by immunotherapy

27 December 2024

27

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Reduction of increased serum neutrophil chemotactic activity following effective hyposensitization in house dust mite allergy

27 December 2024

28

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis

27 December 2024

29

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid

27 December 2024

30

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract

27 December 2024

31

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjunctivitis

27 December 2024

32

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses

27 December 2024

33

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts

27 December 2024

34

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells

27 December 2024

35

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Regulation of the human immune response to ragweed pollen by immunotherapy. A controlled trial comparing the effect of immunosuppressive peptic fragments of short ragweed with standard treatment

27 December 2024

36

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients. Allergen-antibody complex immunotherapy

27 December 2024

37

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs

27 December 2024

38

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Allergic rhinitis to ragweed pollen. I. Reassessment of the effects of immunotherapy on cellular and humoral responses

27 December 2024

39

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever

27 December 2024

40

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Placebo-controlled immunotherapy with Cocos nucifera pollen extract

27 December 2024

41

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever

27 December 2024

42

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Immunotherapy with Alpare in patients with respiratory allergy to Parietaria pollen: a two year double-blind placebo-controlled study

27 December 2024

43

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy

27 December 2024

44

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: a 2-year, double-blind, placebo-controlled study

27 December 2024

46

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis

27 December 2024

47

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Clinical and immunologic evaluation of tyrosine-adsorbed Dermatophagoides pteronyssinus extract: a double-blind placebo-controlled trial

27 December 2024

49

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results

27 December 2024

50

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum

27 December 2024

51

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy.

27 December 2024

52

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study

27 December 2024

55

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes

27 December 2024

57

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study

27 December 2024

58

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Ragweed immunotherapy in adult asthma

27 December 2024

59

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity

27 December 2024

60

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

A 1‐year, placebo‐controlled, double‐blind house‐dust‐mite immunotherapy study in asthmatic adults

27 December 2024

62

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses

27 December 2024

63

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment

27 December 2024

65

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma

27 December 2024

66

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Immunotherapy for cat asthma

27 December 2024

67

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Rush immunotherapy with a standardized Bermuda grass pollen extract

27 December 2024

68

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Immunotherapy in patients allergic to cat and dog dander. I. Clinical results

27 December 2024

69

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Double-blind trial of house-dust mite immunotherapy in asthmatic children resident at high altitude

27 December 2024

71

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

A controlled trial of immunotherapy for asthma in allergic children

27 December 2024

72

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial

27 December 2024

73

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis

27 December 2024

74

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

A placebo‐controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non‐allergic perennial rhinitis

27 December 2024

75

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma

27 December 2024

76

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group

27 December 2024

78

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

The effect of drug therapy on long-term outcome of childhood asthma: a possible preview of the international guidelines

27 December 2024

80

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Survey of fatalities from skin testing and immunotherapy 1985-1989.

27 December 2024

81

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Systemic reactions from allergen immunotherapy

27 December 2024

82

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

Systemic reactions occurring during immunotherapy with standardized pollen extracts

27 December 2024

83

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

A prospective safety-monitoring study of immunotherapy with biologically standardized extracts

27 December 2024

84

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.1998.TB04082.X

27 December 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9636804 AND SRC:MED&resulttype=core&format=json

12 November 2019

1 reference